Center for Cancer Immunology Research
Directors: Patrick Hwu, M.D., and Larry Kwak, M.D., Ph.D.
The Center for Cancer Immunology Research (CCIR) is a one of a kind research program where laboratory and clinical immunologists work side by side to translate groundbreaking discoveries in basic immunology into the development of innovative immunotherapies that instruct our immune system to eliminate cancer and prevent its recurrence.
Since the center's inception in 2003, CCIR investigators have made remarkable progress in the number of high-quality publications, level of research support, and number of investigator-initiated pre-clinical studies/clinical trials.
To learn more about the CCIR, we invite you to read our five-year report (covers 2003 to 2008) and our recent two-year report (covers 2009 and 2010). Click each image below (left: five-year report; right: two-year report) to open a pdf version of the report.
- Peli1 - a potential molecular link between microbial infection and multiple sclerosis
- Adjuvant in cancer vaccine could determine fate of induced tumor-reactive T cells
- SU2C/CRI supports Dream Team efforts in translational immunology research
- MD Anderson welcomes cancer immunotherapy pioneer, James P. Allison, PhD
- HER2 hybrid vaccine reduces recurrence rate of breast cancer
- Canine model helps facilitate clinical development of novel combination therapy for lymphoma
- Discovery of a regulatory T cell specialized in suppressing germinal cell reactions
- Therapeutic melanoma vaccine improves patient response to IL-2 and extends progression-free survival time
- Personalized lymphoma vaccine extends patient disease-free survival time